Super Lawyers
Justia Lawyer Rating for Ronald V. Miller Jr.
Best Law Firms
Avvo Rating - 10
Million Dollar Advocates Forum
Litigator Awards

Tepezza Hearing Loss Lawsuit

Our lawyers are handling Tepezza lawsuits throughout the country.

Tepezza is a drug used to treat the symptoms of thyroid eye disease (TED). Soon after Tepezza was released on the market it was discovered that Tepezza can cause permanent hearing damage and/or tinnitus (ringing in the ears) in some patients. Patients who received Tepezza and suffered hearing damage are now filing Tepezza lawsuits.

If you received Tepezza infusions and subsequently suffered a loss of hearing or other hearing issues, you may be able to file a product liability lawsuit and get financial compensation by a settlement or jury payout.  Our attorneys are currently seeking Tepezza hearing damage cases in all 50 states. Contact us today at 800-553-8082 or reach out to us online.

January 2023 Tepazza Lawsuit Update

January 19, 2023: A group of Tepezza plaintiffs have filed a motion seeking consolidation of ten Tepezza hearing loss lawsuits pending in the Northern District of Illinois.

So we now have a Tepezza class action lawsuit?  Yes and no.  If granted, the motion would result in sort of a mini-MDL within the district in which the cases proceed before a single judge and discovery is consolidated.

Horizon filed a response last week stating that it is opposed to the consolidation request on the grounds that the cases involve substantially different facts. There are a handful of Tepezza cases pending in other federal districts.

January 18, 2023: Lawyers began looking to file Tepezza hearing loss lawsuits in earnest about four months ago.  What have we learned?

We have learned that there are not many Tepezza lawsuits out there.  We have a strong position in developing these cases and we have not had even 100 potential leads. No lawyer we have spoken to has a significant volume of Tepezza lawsuits to file.  This tells us the Tepezza litigation will be small.

But those same lawyers we have talked to universally agree these are strong claims that will have a high settlement value.  Smaller litigation is bad for lawyers but good for victims.  Horizon or Amgen will be able to pay the high settlement amounts a Tepezza claim should garner without

January 17, 2023:  Many victims are interested in knowing what a Tepazza settlement might look like.  We have written a new page projecting Tepazza settlement amounts we anticipate at the conclusion of this litigation.

January 9, 2023: Last month, biopharmaceutical giant Amgen announced a deal to acquire Horizon Therapeutics for $116.50 per share. One of the main goals of the acquisition was to increase Amgen’s rare disease drug portfolio, which includes Tepezza.

Now, however, Amgen investors have filed suit seeking to block the acquisition due to concerns about the Tepezza litigation liabilities.

From a plaintiff’s perspective, the Amgen acquisition would be a good thing because it would mean more resources available to make fair settlement payouts to victims.

Brief History of Tepezza

Tepezza

Tepezza (teprotumumab) is a new prescription drug that is used for the treatment of thyroid eye disease (TED) and a condition known as Graves’ eye disease. TED is a condition in which the eye muscles, eyelids, tear glands and fatty tissue behind the eyes become inflamed. The inflammation is triggered by an abnormal autoimmune response and it can cause the eyes to swell and obstruct vision.

Tepezza was developed by Horizon Therapeutics and it is still under its original patent protection. Tepezza was formally approved by the Food and Drug Administration (FDA) in January 2020. It was the first medication approved for the treatment of thyroid eye disease. Tepezza blocks a specific protein that is believed to be responsible for the development of TED. Tepezza is administered by injection about every 3 weeks for around 5 months.

Horizon obtained FDA approval for Tepezza based on very limited testing and without determining the exact mechanism of action of the drug. The clinical trial which Horizon used for the FDA approval of Tepezza included less than 100 patients.

Study Links Tepezza to Serious Hearing Loss

During the FDA review and approval process for Tepezza, Horizon acknowledged that the drug presented some risk of hearing damage as a potential side effect. However, Horizon represented to the FDA that the hearing loss was “temporary and generally of limited duration,” and claimed that this side effect occurred in less than 10% of patients.   But adverse event reports, the medical literature, and even Horizon’s post-marketing studies suggested that Tepezza causes permanent hearing loss.

Soon after Tepezza was released on the U.S. market, reports of serious hearing damage from patients and doctors began coming in. In early 2021, the results of new research studies on Tepezza showed that not only did Horizon grossly understated the risk of hearing damage associated with Tepezza, it also undersold how serious that hearing damage could be.

In March 2021 the results of a major study were published in the Endocrine Society journal which found that 65% of patients who received Tepezza reported some level of hearing damage or ringing in the ears. This is over 6 times higher than the estimated risk of hearing loss disclosed by Horizon during the FDA approval process. Additional case reports about the risk of hearing loss associated with Tepezza followed.

Horizon’s Failure to Warn About Tepezza and Hearing Loss

Horizon acknowledged to a limited extent in its warnings that hearing damage was a potential side effect of Tepezza infusions. However, the warning was grossly inadequate because it understated the level of risk and did not advise doctors (or patients) about the risk of permanent hearing damage or the need for monitoring. Horizon knew or should have reasonably known about this potential risk associated with Tepezza and warned doctors and patients accordingly.

Tepezza Hearing Loss Lawsuits

In summer 2022, patients who received Tepezza and subsequently suffered hearing damage or tinnitus began filing product liability lawsuits against Horizon. The Tepezza lawsuits allege that Horizon negligently failed to properly warn doctors and patients about the true level of hearing loss risk presented by Tepezza.

At least two Tepezza hearing damage lawsuits have been filed against Horizon in federal court so far. The cases were filed in August and September in the Northern District of Illinois which is where Horizon has its corporate headquarters.

The plaintiffs in these Tepezza lawsuits claim that suffered hearing damage as a result of receiving Tepezza infusions for the treatment of their TED. The lawsuits claim that the lack of an adequate warning about the risk of hearing damage from Tepezza left the plaintiffs and their doctors unaware of the potential harm that could be caused by the drug. The lawsuits bring claims based on negligent failure to warn and defective design.

Many more Tepezza hearing loss lawsuits are expected to be filed as more Tepezza patients suffer damage to their hearing. At this point, the Tepezza lawsuits have not been consolidated into a class action MDL. But if many more Tepezza lawsuits  get filed that could happen in the future (or some modified version of a class action lawsuit as we are now seeing in Illinois in January 2023).

So far, Horizon’s defense strategy to every Tepezza lawsuit has been to seek dismissal because the plaintiffs’ state law tort claims are preempted by federal law. The argument (which we see all the time in pharmaceutical tort cases) is that the warning labels on Tepezza are governed by federal law and regulations which preempt the state law tort claims.

Estimated Settlement Payout Value of Tepezza Hearing Lawsuits

There is no way of knowing for certain how much Tepezza hearing damage lawsuits could potentially be worth in settlement or at trial. The first Tepezza cases have only recently been filed and there are too many variables at this stage to know for certain whether these cases will be viable or not. The best we can do is provide a reasonable estimate of what a successful Tepezza hearing loss lawsuit could be worth in a settlement.

Our attorneys predict that Tepezza hearing loss cases with favorable facts may have a payout value at settlement of $140,000 to $250,000. The precise value of a specific case will depend on various factors, including the age of the plaintiff and whether they had any preexisting hearing issues. Cases involving a major, permanent hearing loss in relatively young plaintiffs could be worth much more.

Contact Us About a Tepezza Hearing Damage Lawsuit

Our firm is currently seeking Tepezza hearing damage lawsuits across the country. If you took Tepezza for treatment of TED and you subsequently suffered hearing damage, hearing loss, or permanent ringing in the ears (tinnitus) contact our office today for a free consultation at 800-553-8082 or contact our team online.  We want to help you.

Client Reviews
Client Reviews
★★★★★
They quite literally worked as hard as if not harder than the doctors to save our lives. Terry Waldron
★★★★★
Ron helped me find a clear path that ended with my foot healing and a settlement that was much more than I hope for. Aaron Johnson
★★★★★
Hopefully I won't need it again but if I do, I have definitely found my lawyer for life and I would definitely recommend this office to anyone! Bridget Stevens
★★★★★
The last case I referred to them settled for $1.2 million. John Selinger
★★★★★
I am so grateful that I was lucky to pick Miller & Zois. Maggie Lauer
★★★★★
The entire team from the intake Samantha to the lawyer himself (Ron Miller) has been really approachable. Suzette Allen
★★★★★
The case settled and I got a lot more money than I expected. Ron even fought to reduce how much I owed in medical bills so I could get an even larger settlement. Nchedo Idahosa